Molnupiravir is an antiviral medication that has gained attention for its potential use in treating COVID-19 and other viral infections.
Molnupiravir is a prodrug, which means it is metabolized in the body into its active form. The active form of Molnupiravir works by inhibiting the replication of RNA viruses. It does this by causing mutations in the viral genetic material, which can lead to errors during viral replication and ultimately reduce the ability of the virus to reproduce.
Molnupiravir was originally developed as a potential treatment for influenza. However, its broad-spectrum antiviral activity has led to investigations into its effectiveness against other RNA viruses, including coronaviruses.
| Technical Parameter | Value |
|---|---|
| Generic Name | EIDD-2801 (2349386-89-4) |
| Indication | Treatment of COVID-19 (Cat FIP Treatment) |
| Country of Origin | China |
| Shipping Method | Air (UPS, FedEx, TNT, EMS) or Sea |
| Shelf Life | 2 years |
| Purity | 99% |
| CAS | 2349386-89-4 |
| COA | Available |
| Molecular Weight | 329.31 g/mol |
Molnupiravir gained significant attention during the COVID-19 pandemic as a potential oral antiviral treatment for SARS-CoV-2, the virus that causes COVID-19. Clinical trials have been conducted to evaluate its efficacy and safety in COVID-19 patients.
Studies have shown that Molnupiravir can reduce the duration of viral shedding and symptoms in COVID-19 patients when administered early in the course of the infection. It is believed to help limit the spread of the virus within the body and potentially reduce the severity of the illness.
1~25kgs packaging: Aluminium bag inside, Carton box outside.
25kgs packaging: Plastic bag inside, Fiber drum outside
